A recent trial looked to compare the efficacy and safety of pembrolizumab (Keytruda) with the standard of care for the treatment of head and neck squamous cell carcinoma (SCC).
A recent trial looked to compare the efficacy and safety of pembrolizumab (Keytruda) with the standard of care for the treatment of head and neck squamous cell carcinoma (SCC).
Researchers conducted a randomized, open-label, phase 3 study across 97 medical centers in 20 different countries. The trial enrolled patients with SCC whose disease had progressed during or after platinum-containing treatment for recurrent or metastatic disease (or both), or patients whose disease recurred or progressed within 3 to 6 months of previous multimodal therapy containing platinum for locally advanced disease. Patients were then randomized 1:1 to receive pembrolizumab 200 mg every 3 weeks or investigator’s choice of standard doses of methotrexate, docetaxel, or cetuximab (standard of care group).
The trial enrolled 495 patients, of whom 247 were randomized to receive pembrolizumab every 3 weeks and 248 were randomized to receive the standard of care. Researchers found that 37% of patients taking pembrolizumab survived for at least 1 year, compared with 26.5% of patients receiving the standard of care. The median overall survival was 8.4 (95% CI, 6.4-9.4) months with pembrolizumab, and 6.9 (95% CI, 5.9-8.0) months with the standard treatment.
The response rates were similar among the 2 groups, at 14.6% in the pembrolizumab group versus 10.1% in the standard of care. The most common treatment-related adverse event was hypothyroidism with pembrolizumab (in 33 [13%] patients) and fatigue with the standard of care (in 43 [18%] patients).
“The clinically meaningful prolongation of overall survival and favorable safety profile of pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma support the further evaluation of pembrolizumab as a monotherapy and as part of combination therapy in earlier stages of disease,” wrote the study authors.
Reference
Cohen E, Soulieres D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): a randomized, open-label, phase 3 study [published online November 30, 2018]. Lancet. doi: 10.1016/S0140-6736(18)31999-8.
Dr Guru Sonpavde: Nivolumab Plus Gemcitabine-Cisplatin Holds Promise in Urothelial Cancer
November 30th 2023Urothelial carcinoma has long been treated with chemotherapy as the frontline standard of care, but recent trial results in the space have potential to add to the treatment armamentarium and improve outcomes for the first time in decades.
Read More
The FDA has approved pembrolizumab (Keytruda) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Read More
Addressing Financial Toxicity With Navigators and Better Conversations Around Decision Making
June 5th 2018Financial toxicity impacts a lot more than a patient's finances—it leads to nonadherence and poorer health outcomes. Financial navigators are increasingly being used to be proactive about addressing high healthcare costs and the resulting financial toxicity.
Listen
Maintenance Durvalumab Plus Olaparib Improves PFS in Advanced or Recurrent Endometrial Cancer
November 1st 2023The addition of durvalumab to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib significantly improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial.
Read More